The Declining Efficacy of Naltrexone Pharmacotherapy for Alcohol Use Disorders Over Time: A Multivariate Meta-Analysis-Reference-Cited by-同舟云学术

The Declining Efficacy of Naltrexone Pharmacotherapy for Alcohol Use Disorders Over Time: A Multivariate Meta-Analysis

Published:2013-02-07 Issue:6 Volume:37 Page:1064-1068
ISSN:0145-6008
Container-title:Alcoholism: Clinical and Experimental Research
language:en
Short-container-title:Alcohol Clin Exp Res

Author:

Del Re A. C.¹,Maisel Natalya¹,Blodgett Janet¹,Finney John¹

Affiliation:

1. HSR&D Center for Health Care Evaluation; VA Palo Alto Health Care System (152MPD); Stanford University Medical School; Menlo Park; California

Publisher

Wiley

Subject

Psychiatry and Mental health,Toxicology,Medicine (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acer.12067/fullpdf

Reference17 articles.

1. Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time;Del Re;J Clin Psychopharmacol

2. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?;Feinn;Alcohol Clin Exp Res,2005

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying neurofunctional domains across substance use disorders;The American Journal of Drug and Alcohol Abuse;2024-07-03

2. Evidence of subgroup differences in meta‐analyses evaluating medications for alcohol use disorder: An umbrella review;Alcohol: Clinical and Experimental Research;2023-12-15

3. Precision medicine in alcohol use disorder: Mapping etiologic and maintenance mechanisms to mechanisms of behavior change to improve patient outcomes.;Experimental and Clinical Psychopharmacology;2022-11-10

4. Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder;Frontiers in Psychiatry;2022-06-09

5. Behavioral economic analysis of topiramate pharmacotherapy for alcohol: a placebo-controlled investigation of effects on alcohol reinforcing value and delayed reward discounting;Psychopharmacology;2022-01